Up to date information about new findings for diabetic kidney diseases. Increase your knowledge on sodium/glicose cotransporter inhibitor (SGLT-2) and how it is reducing kidneys outcomes by a deep explanation of its mechanisms of action and renal pathophysiology.

Peter Stenvinkel, Christoph Wanner, Andeera Levin


Karolinska Institutet Stockholm / Sweden,University Hospital Wuerzburg / Germany, University British Columbia, Vancouver / Canada



#diabetesandkidney, #DKDfinding, DKDlectures, #DKDupdates #nephrologycampus

свернуть